Mirum Pharmaceuticals, Inc. - 10-Q Filing

Mirum Pharmaceuticals reports Q3 2026 financial results including updates on Livmarli sales and convertible debt obligations.

SEC EDGAR ·

Tickers: $MIRM

Read the full article at SEC EDGAR

More Regulatory news